news, journals and articles from all over the world.
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC).
“Senotherapy,” a treatment that uses small molecule drugs to target “senescent” cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute. The study was published in Nature Cell Biology.
Using next-generation RNA sequencing techniques, a team of scientists from the University of Michigan Rogel Cancer Center has uncovered the gene signature of chromophobe renal cell carcinoma (ChRCC) and have extensively tested the expression of three new biomarkers. The subtype is the third most common type of renal cell carcinoma, comprising about 5% of cases.
New therapeutic strategies proposed for some lung and kidney cancers. Study shows cancers with high levels of the SLC7A11 gene may respond to glucose transporter inhibitor treatment.
New research shows that both strands of microRNA cooperate to drive growth and aggressiveness across cancer types, suggesting that these molecules may be more central in deadly cancers than previously thought.
Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.” Knowing more about the genome is crucial given that mitochondria play important roles in tumorigenesis.
The famous cancer gene p53, which was thought to be less relevant in kidney cancer, may play a larger role than previously appreciated, suggesting new potential for treatment.
The Kidney Cancer Association is recognizing the research accomplishments and leadership achievements of W. Kimryn Rathmell, MD, PhD, with its most prestigious honor, the Eugene P. Schonfeld Award.
Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase IB study
Mohit Gupta, MD, has been appointed director of urologic oncology and brings the latest surgical techniques in the treatment of prostate and urinary cancers to NYU Langone Hospital–Brooklyn.
Mohit Gupta, MD, has been appointed director of urologic oncology and brings the latest surgical techniques in the treatment of prostate and urinary cancers to NYU Langone Hospital–Brooklyn.
Penn Study Investigated Real-World Treatment Outcomes Among Medicare Patients PHILADELPHIA—Many elderly patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials to treat the kidney cancer—are seeing overall survival benefits from treatment with targeted therapies, according to…
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu